Hosted on MSN6d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with ...
InnovationRx: Fatal Drug Overdoses Are Falling – But Medicaid Cuts Could Halt Progress
In this week’s edition of InnovationRx, we look at the trend in fatal drug overdoses, 23andMe’s bankruptcy, the new CDC ...
pharmaphorum3d
Axsome bounces back as FDA clears depression drug
That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks.
pharmaphorum4d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Pharmabiz3d
Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of Kloxxado (naloxone HCl) nasal spray 8 mg, by Health Canada for the treatment of ...
Verywell Health on MSN3d
Afrin vs. Flonase: How Do They Compare for Nasal Congestion?
Afrin and Flonase are over-the-counter nasal sprays. Learn how they compare in effectiveness, side effects, and safety to ...
Yahoo Finance6d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...
Benzinga.com2d
FDA Calendar
Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...
Sun Sentinel6d
Johnson & Johnson plans $55 billion in US investments over the next four years
Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants. A number of companies have highlighted ...